PP-152 Therapy with Transmetil for patients with depressed emotion and chronic liver failure in hepatitis B: an initial study  by Zheng, Y.-B. et al.
Poster Presentations, Poster Session End Stage Liver Diseases and Complications S87
Methods: Works studying the association between
polymorphisms of rs12979860 or rs8099917 and the impact
on HCV treatment were retrieved in PubMed. After
evaluated independently by two researchers, data on
the distribution of patients reaching sustained virological
response (SVR) in different genotypes of the qualiﬁed studies
was abstracted and the summary ORs were calculated using
the relevant effect model of meta-analysis based on the
heterogeneity results in Stata 10.0 software.
Results: Twenty three studies that met the inclusion
criteria were included in the analysis, of which 9 were
on rs12979860, 8 on rs8099917 and 6 on both. Comparing
to subjects with the rs12979860 CT/TT genotype, HCV
infected patients carrying the CC genotype were more
likely to reach SVR after the PegIFN-RVB therapy (OR=3.18,
95%CI: 2.33 4.35). A similar result was observed in subjects
carrying rs8099917 TT genotype comparing to TG/GG
(OR=2.37, 95%CI: 1.73 3.23). As to the subgroup analysis,
those positive results above could only be observed in
the HCV genotype 1 group, but not in subjects infecting
HCV genotype non-1. The publication bias analysis had no
statistically signiﬁcant results.
Conclusion: rs12979860 and rs8099917 were involved in
the effects of HCV treatment with PegIFN-RVB, but this
impact could only be observed in relatively difﬁcult-to-treat
genotype 1 subjects.
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Thyroid dysfunction can be affected as a complication of
interferon therapy due to HCV infection. The aims of the
present study were to investigate the effect of interferon
therapy on the thyroid function on Egyptian patients with
HCV infection.
The study includes 60 HCV infected patients with normal
baseline levels of TSH. The patients receive a subcutaneous
pegylated interferon alfa-2b weekly in addition to oral
ribavirin (1000 1200mg/d). The patients were suspected
to complete history and clinical examination, with special
emphasis to hepatic and thyroid disorders. Before the start
of interferon therapy, serum TSH, thyroglobulin-Ab (TG-Ab)
and antiperooxidase antibodies (TPO-Ab) were measured.
Three months after interferon therapy serum levels of TSH
were performed to all patients, patients with abnormal TSH
were suspected to the measurements of FT3, FT4, TPO-Ab,
TG-Ab and thyroid stimulating immunoglobulin levels (TSI).
After 3 months of interferon therapy, 48 patients (80%)
had normal TSH and 12 patients (20%) had abnormal
TSH. Out of 12 patients had abnormal TSH, 10 patients
(16.6%) had high serum levels of TSH (hypothyroidisms),
while the remaining 2 patients (3.4%) had low serum
levels of TSH (hyperthyroidism). Out of 10 patients with
hypothyroidism, 6 patients (10%) had overt hypothyroidism
and 4 patients (6.6%) had subclinical hypothyroidism. All
patients with abnormal TSH had a signiﬁcant higher levels
of TG-Ab, TPO-Ab and STI. Out of two patients with
hyperthyroidism, one patient presented by clinical pictures
of overt hyperthyroidism, while the other patient presented
by subclinical hyperthyroidism.
In conclusion, the incidence of thyroid dysfunction during
pegylated interferon therapy in patients with HCV is 20%;
hypothyroids was more common than hyperthyroidism. The
patients most at risk for thyroid dysfunctions are people
with preexisting TPO-Abs. Patients with HCV infection
under pegylated interferon and ribavirin therapy should
be screened for thyroid dysfunction before and during
treatment.
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Introduction: CLD is one of the most common health
problems in Egypt due to the prevalence of bilharaiasis
as well as viral hepatitis. The way in which the family copes
with and adapts to chronic illness of one of its members has
a strong impact on the physical and psychosocial well-being
of all members and on the shape and duration of the clinical
course of the illness itself. The family doctor therefore
should be able to evaluate the families’ adaptation to
illness and to promote successful coping strategies where
necessary. The aim of this study is to improve family
function of patients with CLD through detection of family
dysfunction. The detection of family function is the ﬁrst
step in this regard.
Methodology: This study was cross sectional descriptive
study carried in communicable disease and research center
in Suez, its target population was adult patients of
both sexes with CLD. Total number of the sample was
233 patients. Each patient was subjected to the following:
1) Personal, social, geographic assessment.2) History and
physical examination. 3) Biochemical testing for Liver
function evaluation. The Assessment of family function was
done by using (FACESII).
Results: Current study showed that regarding to cohesion,
it was found that 70.4% of patients were balanced while
29.6% were extreme. Regarding to adaptability 66.1% were
balanced, while 33.9% were extreme. It found that 53.6% of
the patients were dysfunction families (mid range, extreme
family function), while 46.6% were balanced (function
families).
Conclusion: The present study concluded that, family
dysfunction is a considerable problem among patient with
CLD. It was no signiﬁcantly associated with almost all socio-
demographic except age of the patient, there were also
no signiﬁcantly associated with severity of CLD, number of
Symptoms and sign of CLD except gynecomastia (for males)
and abdominal swelling.
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Background and Objective: To explore the curative effect
of Transmetil in the treatment for patients with with
depressed emotion and Chronic liver failure in hepatitis B.
Methods: All 49 patients with Chronic liver failure in
hepatitis B were randomly divide into the experiment group
(medical synthetic treatments combined with Transmetil,
n = 32) and the control group (only medical synthetic
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treatments, n = 17), Clinical effectiveness were assessed
with the Hamilton Anxiety Scale (HAMA17) by treatment
before and after 2 weeks, 4 weeks.
Results: Beginning at treatment Week2, the score of
the HAMA decreased gradually in the experiment group,
however there was no signiﬁcant difference in the score of
the HAMA between the 2 groups (P> 0.05), and the score of
the HAMA decreased more signiﬁcantly in the experiment
group by treating weeks 4. The score of the HAMA in the
control group change was signiﬁcantly higher than seen in
the experiment group (P< 0.05).
Conclusions: Transmetil has precise effectiveness in the
treatment for those patients with with depressed emotion
and Chronic liver failure in hepatitis B.
Table. Comparison of HAMA scores between two groups before and after
treatment
Group Before After treatment
treatment Week 2 Week 4
Experimental (n = 25) 13.34±3.86 10.54±4.11* 8.04±2.52**
Control (n = 13) 12.85±4.13 11.27±5.23* 11.89±3.78*
Data are the mean±SE, n = 38.
*P > 0.05, **P < 0.05 compared with treatment before; *P > 0.05, **P < 0.05
compared with the control group respectively.
PP-153 Assessment of liver function by Methacetin C13
breath test pre-and post liver resection in HCC
patients in Mongolia
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(MASLD), 22 Health Sciences University of Mongolia,
3National Cancer Center of Mongolia, Mongolia
Aim: Our aim was to assess the feasibility of Methacetin
breath tests in decreasing mortality during or after liver
resection, predict complications and liver failure after
the resection. To the best of our knowledge there is no
study that checks liver function using Methacetin by oral
administration (indeed there is one study that uses IV
administration).
Method: Methacetin C13 breath test was kindly donated
by Beijing Richen Science and Technology Co., Ltd. 10
empty breaths were collected before each measurement
and 75mg/80ml methacetin was orally administered. After
administration 9 breaths at 10, 20, 30, 40, 50, 60, 80,
100 and 120 minutes were collected in the bags provided
by the manufacturer. Breath test was performed on the
day before operation, post operation days 1 and 10.
Patients with projected resection of more than 20% of the
liver were included in the study. Additional parameters
like liver enzymes, Child-Pugh score, platelets, albumin,
CT volumetry were assessed. Total of 42 patients were
included in the study, out of which 5 were healthy controls.
23 patients canceled operation because of insufﬁcient
liver function. 14 patients participated until the last
measurement of day 10 at National Cancer Center of
Mongolia. Three parameters of the methacetin breath test:
methacetin concentration after 30 min of administration
CUM30, highest concentration of methacetin DOB peak, and
calculated liver function using the software provided by the
manufacturer were obtained after each measurement.
Result: 5 healthy controls had the mean DOB peak value of
29.056, CUM30 of 91.56 and liver function 114.
When 20% of the liver was resected Methacetin
concentration was decreased by 47.09% (DOB peak), 72.1%
(CUM30), 63.22% (calc. liver function); when 35% resected
45.33%, 73.35%, and 74.28%; when 40% cut: 39.04%, 99.3%,
99.3%; when 50% cut 67.38%, 81.97%, 75.2%; when 65%
cut: values were 37.51%, 54.27% and 42.97% respectively.
All patients were Child-Pugh A, and mean albumin was
3.8 g/dl and platelets were 229×109/L, ALT 179IU/L and AST
162IU/L respectively. In terms of predicting complications
we observed DOB peak has the most meaningful results with
5 out of 6 patients with post operative complications had a
value of <20, while 6 out of 7 patients without complications
had values >20.
Conclusion: 3 parameters of the methacetin breath test
(methacetin concentration after 30 min of administration
CUM30, highest concentration of methacetin DOB peak,
and calculated liver function using the software provided
by the manufacturer) were compared the amount of liver
cut away. The closest parameter to the amount of liver
resected was the highest concentration of methacetin DOB
peak, whereas CUM 30 and liver function did not match
the amount as that of DOB peak. We suggest the cut off
value of DOB peak at 20. This method is non-invasive,
non-toxic, direct method to assess liver function with high
predictive and dynamic range in regard to residual liver
function. The sensitivity of the methacetin test to predict
post-operative complications were 83%, and the speciﬁcity
stands at 85% with PPV (Positive Predictive Value) = 83%,
and NPV (Negative Predictive Value) = 85% respectively. The
most common post-operative complications we encountered
were ascitis and wound infections.
Liver cirrhosis
Control
(n = 5)
Non cirrhosis
(n = 8)
Child Pugh
(n = 5)
DOB peak 29.06 25.29 18.56
CUM 30 91.56 94.01 64.32
Liver function 114 104.79 77.71
Complications after surgery
Control
(n = 5)
Complication
(n = 7)
Non complication
(n = 6)
DOB peak 29.06 26.56 18.21
CUM 30 91.56 89.84 74.12
Liver function 114 106.87 79.79
PP-154 Effects of Alzet mini-osmotic pumps controlled
release of IGFBPrP1 on liver and lung in mice
L.X. Liu1, Q.Q. Zhang1 *, H.Y. Zhang1. 1The First Hospital
of Shanxi Medical University, China
Objectives: IGFBPrP1 was released at a continuous constant
dose by Alzet mini-osmotic pump which was implanted
subcutaneously of wild-type mice, Compare the effects
of IGFBPrP1 on liver and lung tissues and explore its
mechanism.
Methods: Mice were randomly divided into normal group,
sham-operated group and Operation group. We used
rmIGFBPrP1 which was released by capsule osmotic pump
to make the model. Sham-operated group was only treated
by control operation. HE and Picrosirius red staining were
used to evaluate pathomorphological changes and collagen
generation. The expression and distribution of IGFBPrP1,
Collagen-III, Smad3, p-Smad2/3 protein in mice hepatic and
lung tissues were tested by immunohistochemistry methods.
Apoptosis of hepatic cells was investigated by TUNEL.
